How do we manage t(11;14) plasma cell disorders with venetoclax?
Author:
Affiliation:
1. Multiple Myeloma and Amyloidosis Program Columbia University Irving Medical Center New York New York USA
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18243
Reference43 articles.
1. Hallmarks of Cancer: The Next Generation
2. The Bcl-2 apoptotic switch in cancer development and therapy
3. BCL2 and MCL1 inhibitors for hematologic malignancies
4. ABT-737 is highly effective against molecular subgroups of multiple myeloma
5. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11
2. Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression;Leukemia & Lymphoma;2024-08
3. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy;Amyloid;2024-07-02
4. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects;Hematology;2023-12-27
5. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma;Cancers;2023-12-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3